OverviewSuggest Edit

Incyte is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. The Company develops Jakafi (ruxolitinib), a drug for the treatment of intermediate or high-risk myelofibrosis, a type of myeloproliferative disorder that affects the bone marrow, and for polycythemia vera when there has been an inadequate response to or intolerance of hydroxyurea.

TypePublic
Founded1991
HQTalleyville, US
Websiteincyte.com
Employee Ratings3.3

Latest Updates

Employees (est.) (Dec 2018)1,367(+14%)
Job Openings69
Revenue (FY, 2018)$1.9 B(+23%)
Share Price (Mar 2019)$85.3 (-1%)

Key People/Management at Incyte

Hervé Hoppenot

Hervé Hoppenot

Chairman, President, and Chief Executive Officer
Jonathan e Dickinson

Jonathan e Dickinson

Senior Vice President, General Manager, Europe
Lothar H Finke

Lothar H Finke

Head of Clinical Development and General Manager, Japan
David W Gryska

David W Gryska

Executive Vice President, Chief Financial Officer
Reid M Huber

Reid M Huber

Executive Vice President, Chief Scientific Officer
Vijay Iyengar

Vijay Iyengar

Executive Vice President, Global Strategy and Corporate Development
Show more

Incyte Office Locations

Incyte has offices in Talleyville, Geneva, Madrid, Milan and in 6 other locations
Talleyville, US (HQ)
Talleyville, DE 19803, USA
Wien, AT
DC Tower 1 7 Donau-City-Straße
Boulogne-Billancourt, FR
35 ter avenue André Morizet
Planegg, DE
9 Fraunhoferstraße
Milan, IT
Via Fabio Filzi 25/A
Amsterdam, NL
Paasheuvelweg 25
Show all (10)
Report incorrect company information

Incyte Financials and Metrics

Incyte Revenue

Incyte's revenue was reported to be $1.88 b in FY, 2018
USD

Revenue (FY, 2018)

1.9b

Net income (FY, 2018)

109.5m

EBIT (FY, 2018)

129.2m

Market capitalization (22-Mar-2019)

18.3b

Closing stock price (22-Mar-2019)

85.3

Cash (31-Dec-2018)

1.2b
Incyte's current market capitalization is $18.3 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

354.9m511.5m753.8m1.1b1.5b1.9b

Revenue growth, %

44%47%47%

General and administrative expense

110.0m196.6m303.3m366.4m434.4m

R&D expense

260.4m479.5m581.9m1.3b1.2b
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

85.1m89.8m99.6m198.1m159.3m163.0m187.6m263.5m246.3m269.5m384.1m326.4m381.5m382.3m521.5m449.7m

General and administrative expense

26.4m37.0m40.9m39.4m44.9m51.7m47.6m64.6m66.8m75.8m87.2m90.1m91.3m121.5m108.0m96.5m

R&D expense

71.7m75.6m84.7m88.5m118.4m112.4m132.1m156.8m120.3m143.2m408.0m201.8m269.6m303.1m298.1m292.5m

Operating expense total

98.3m112.7m125.8m128.2m166.2m170.4m187.7m227.4m201.7m247.2m517.4m319.2m366.6m449.4m438.3m418.6m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

471.4m452.3m521.4m652.3m899.5m1.2b

Accounts Receivable

35.4m57.9m114.5m148.8m266.3m307.6m

Inventories

406.0k20.5m1.8m4.1m6.5m7.0m

Current Assets

555.8m699.2m842.4m994.2m1.5b1.8b
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(83.1m)(48.5m)6.5m104.2m(313.1m)109.5m

Depreciation and Amortization

58.4m52.2m55.0m

Inventories

(6.6m)(4.1m)98.0k4.0m4.9m4.0m

Accounts Payable

5.1m5.4m5.6m43.8m(7.9m)36.2m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(40.3m)(34.0m)(70.8m)(11.5m)(18.4m)(9.1m)(48.6m)24.0m58.5m95.3m(187.1m)(199.6m)(163.5m)(41.1m)11.3m40.4m

Depreciation and Amortization

23.9m40.9m15.0m27.4m39.3m13.4m26.9m40.7m

Inventories

(6.6m)(506.0k)(517.0k)(2.6m)2.4m(1.0m)(830.0k)752.0k1.7m4.4m790.0k4.5m4.7m1.9m1.9m3.0m

Accounts Payable

4.3m(1.2m)8.1m7.5m26.6m4.7m2.9m1.8m8.9m25.7m10.7m(6.5m)(5.7m)6.4m7.9m27.8m
USDY, 2018

Revenue/Employee

1.4m

Financial Leverage

1.4 x
Show all financial metrics
Report incorrect company information

Incyte Online and Social Media Presence

Embed Graph
Report incorrect company information

Incyte News and Updates

Worldwide Castleman Disease Treatment Market Research, Size, Share, Overview, Future Trends, Scope, outlook | Top Key Players - Johnson & Johnson, F.Hoffmann-La Roche, Bristol-Myers Squibb, Merck, Pfizer, Hospira, Incyte, Novartis | 2019-2025

Summary: A new market study, titled “Discover Global Castleman Disease Treatment Market Upcoming Trends, Growth Drivers and Challenges” has been featured on WiseGuyReports. Posted via Industry Today. Follow us on Twitter @IndustryToday

Kidney Cancer Treatment Drugs Market Analyzed by Business Growth| AstraZeneca, Aveo Pharmaceuticals, Bayer, Exelixis, Incyte, Merck, Roche, Pfizer, Bristol-Myers Squibb

Kidney Cancer Treatment Drugs Market Report aims to define, describe, and forecast on the basis of Market size, share, types, overview, top key vendors. This research report provides analysis and information according to market segments such as geography, technology and application. Posted via Indus…

Global Vitiligo Market Research Report 2018-2024 Featuring AXIM Biotechnologies, Boston Pharma, Bristol-Myers Squibb, Castle Creek Pharma,Clinuvel Pharma, Dermavant Sciences, Incyte & JN Biosciences

DUBLIN, Dec. 18, 2018 /PRNewswire/ -- The "Global Vitiligo Market, Patients by Countries, Drugs, Companies, Clinical Study, Growth Drivers, and Challenges" report has been added to ResearchAndMarkets.com's offering. Global Vitiligo market will be US$ 2.4 Billion by the year 2024. Vitiligo ...

Innovent and Incyte Announce Strategic Collaboration and Licensing Agreement for Three Clinical-stage Product Candidates in China

SUZHOU, China, Dec. 16, 2018 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801) and Incyte (NASDAQ:INCY) today announced that the companies, through their respective subsidiaries, have entered into a strategic collaboration agreement for three clinical-stage product...

XOMA Acquires Royalty Interest Position from Agenus on Seven Assets Being Developed by Merck and Incyte

EMERYVILLE, Calif., Sept. 21, 2018 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), announced today that for $15.0 million, it has acquired from Agenus (NASDAQ: AGEN) a partial interest position in the rights to potential milestone and royalty payments associated with seven immuno-oncology ant…

Agenus Receives Milestone Payment from Incyte

LEXINGTON, Mass., Sept. 17, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies1, announced today receipt of a cash milestone from Incyte for the initiation of a...
Show more
Report incorrect company information

Incyte Frequently Asked Questions

  • When was Incyte founded?

    Incyte was founded in 1991.

  • Who are Incyte key executives?

    Incyte's key executives are Hervé Hoppenot, Jonathan e Dickinson and Lothar H Finke.

  • How many employees does Incyte have?

    Incyte has 1,367 employees.

  • What is Incyte revenue?

    Latest Incyte annual revenue is $1.9 b.

  • What is Incyte revenue per employee?

    Latest Incyte revenue per employee is $1.4 m.

  • Who are Incyte competitors?

    Competitors of Incyte include Reata Pharmaceuticals, Ironwood Pharmaceuticals and Biogen.

  • Where is Incyte headquarters?

    Incyte headquarters is located at Talleyville, DE 19803, USA, Talleyville.

  • Where are Incyte offices?

    Incyte has offices in Talleyville, Geneva, Madrid, Milan and in 6 other locations.

  • How many offices does Incyte have?

    Incyte has 10 offices.